Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of HS636 alone or with nab-paclitaxel in advanced triple-negative breast cancer
CTR20212163Phase 2Suspended
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of sudubrilimab in triple-negative breast cancer (TNBC) (3 arms), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd. Primary endpoints: Phase Ib stage 1 safety, Phase Ib stage 2 safety and 1 more. Started Oct 2021; status: suspended.
02
Drugs
sudubrilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20212163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212163.